Five years from the start of the COVID-19 pandemic, numerous academic studies have shown how the novel coronavirus affects ocular health.
Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback